1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea | 1321451-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea
• 英文别名: 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-7-yl)oxy]phenyl]urea
• CAS: 1321451-78-8
• 化学式: C₂₇H₂₆FN₇O₃
• 分子量: 515.547
• InChiKey: IBCZSSWQZVYRBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl 4-(4-(tert-butoxycarbonyl)amino-3-fluorophenoxy)-2-aminopyridin-3-yl-carbamate 在 sodium ethanolate 、 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 、 mineral oil 为溶剂， 反应 36.67h， 生成 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(1-N-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)urea
  参考文献：
  名称：

  [EN] 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY
  [FR] 1-(5-TERT-BUTYL-2-PHÉNYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-MÉTHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHÉNYL]-URÉE ET COMPOSÉS ASSOCIÉS, ET LEUR UTILISATION DANS DES TRAITEMENTS

  摘要：

  公开号：

  WO2011092469A8

文献信息

• 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL-2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY
  申请人：Springer Caroline

  公开号：US20120283288A1

  公开（公告）日：2012-11-08

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

  本发明一般涉及治疗化合物领域，更具体地涉及以下式(I)的某些化合物（为方便起见，本文中统称为“IP化合物”），这些化合物可用于治疗癌症，例如由突变RAS（“突变RAS癌症”）特征化的癌症。本发明还涉及包含这种化合物的药物组合物，以及使用这种化合物和组合物治疗癌症，例如突变RAS癌症。
• 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
  申请人：Springer Caroline

  公开号：US08815896B2

  公开（公告）日：2014-08-26

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

  本发明涉及治疗化合物领域，更具体地涉及以下公式（I）的某些化合物（为方便起见，在此统称为“IP化合物”），其中包括用于治疗癌症的化合物，例如，由突变RAS（“突变RAS癌症”）特征化的癌症。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物治疗癌症，例如，突变RAS癌症。
• 1-(5-TERT-BUTYL-2-PHENYL-2H-PYRAZOL-3-YL)-3-[2-FLUORO-4-(1-METHYL- 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-7-YLOXY)-PHENYL]-UREA AND RELATED COMPOUNDS AND THEIR USE IN THERAPY
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20140357663A1

  公开（公告）日：2014-12-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

  本发明通常涉及治疗化合物领域，更具体地涉及以下式子的某些化合物（为方便起见，在此统称为“IP化合物”），这些化合物等可用于治疗癌症，例如，由突变RAS（“突变RAS癌症”）特征化的癌症。本发明还涉及包含这种化合物的药物组合物以及在治疗癌症，例如突变RAS癌症中使用这种化合物和组合物的用途。
• 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US09120789B2

  公开（公告）日：2015-09-01

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

  本发明通常涉及治疗化合物领域，更具体地涉及以下式子的某些化合物（为方便起见，此处统称为“IP化合物”），其中，这些化合物可用于治疗癌症，例如，由突变RAS（“突变RAS癌症”）特征化的癌症。本发明还涉及包含这些化合物的药物组合物，以及在治疗癌症，例如突变RAS癌症中使用这些化合物和组合物的用途。
• SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：EP3828173A1

  公开（公告）日：2021-06-02

  Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention and the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

  公开了本文所述的式 (I) 化合物及其药学上可接受的盐类。这些化合物是血浆卡立克雷因的抑制剂。还提供了包含至少一种本发明化合物的药物组合物，以及涉及使用本发明化合物和组合物、治疗和预防以不需要的血浆卡利克雷因活性为特征的疾病和病症的方法。